{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:01:32Z","timestamp":1791388892511,"version":"4.3.3"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.pharmthera.2020.107580","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T02:19:14Z","timestamp":1590200354000},"page":"107580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["VMAT2 inhibitors for the treatment of hyperkinetic movement disorders"],"prefix":"10.1016","volume":"212","author":[{"given":"Jessa","family":"Koch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khashayar","family":"Dashtipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.pharmthera.2020.107580_bb0005","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2217\/cer-2019-0059","article-title":"Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia","volume":"8","author":"Aggarwal","year":"2019","journal-title":"Journal of Comparative Effectiveness Research"},{"key":"10.1016\/j.pharmthera.2020.107580_bb0010","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107580_bb0015","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107580_bb0020","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/002215540305100806","article-title":"Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors","volume":"51","author":"Anlauf","year":"2003","journal-title":"The Journal of Histochemistry and Cytochemistry"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107580_bb0025","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.31.8.1051","article-title":"Tetrabenazine and movement disorders","volume":"31","author":"Asher","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2020.107580_bb0030","series-title":"Package insert","author":"Austedo","year":"2019"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107580_bb0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/0964704X.2012.664087","article-title":"The chlorpromazine enigma","volume":"22","author":"Baumeister","year":"2013","journal-title":"Journal of the History of the Neurosciences"},{"key":"10.1016\/j.pharmthera.2020.107580_bb0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuint.2013.12.003","article-title":"The vesicular monoamine transporter 2: An underexplored pharmacological target","volume":"73","author":"Bernstein","year":"2014","journal-title":"Neurochemistry International"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107580_bb0045","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/wps.20579","article-title":"Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: A meta-analysis","volume":"17","author":"Carbon","year":"2018","journal-title":"World Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107580_bb0050","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2217\/cer-2017-0065","article-title":"Treatment of tardive dyskinesia with tetrabenazine or valbenazine: A systematic review","volume":"7","author":"Caroff","year":"2018","journal-title":"Journal of Comparative Effectiveness Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107580_bb0055","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.clinthera.2012.06.010","article-title":"Tetrabenazine for the treatment of hyperkinetic movement disorders: A review of the literature","volume":"34","author":"Chen","year":"2012","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107580_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40734-017-0051-5","article-title":"Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease","volume":"4","author":"Claassen","year":"2017","journal-title":"Journal of Clinical Movement Disorders"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107580_bb0065","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18m12278","article-title":"Characterizing treatment effects of valbenazine for tardive dyskinesia: Additional results from the KINECT 3 study","volume":"80","author":"Correll","year":"2018","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107580_bb0070","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1021\/bi00430a040","article-title":"Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter","volume":"28","author":"Darchen","year":"1989","journal-title":"Biochemistry"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107580_bb0075","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1073\/pnas.93.10.5166","article-title":"Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter","volume":"93","author":"Erickson","year":"1996","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107580_bb0080","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.4088\/JCP.17m11777","article-title":"The effects of valbenazine in participants with tardive dyskinesia: Results of the 1-year KINECT 3 Extension Study","volume":"78","author":"Factor","year":"2017","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107580_bb0085","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study","volume":"88","author":"Fernandez","year":"2017","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107580_bb0090","first-page":"1317","article-title":"Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia","volume":"90","author":"Fernandez","year":"2019","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107580_bb0095","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/jnnp.66.1.52","article-title":"Differences in duration of Huntington\u2019s disease based on age at onset","volume":"66","author":"Foroud","year":"1999","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2020.107580_bb0100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1471-2377-9-62","article-title":"Tetrabenazine as anti-chorea therapy in Huntington disease: An open-label continuation study. Huntington Study Group\/TETRA-HD Investigators","volume":"9","author":"Frank","year":"2009","journal-title":"BMC Neurology"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107580_bb0105","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamaneurol.2017.1352","article-title":"Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea","volume":"74","author":"Frank","year":"2017","journal-title":"JAMA Neurology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107580_bb0110","first-page":"133","article-title":"Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications","volume":"54","author":"Glazer","year":"1993","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107580_bb0115","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/jpet.116.239160","article-title":"Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites","volume":"361","author":"Grigoriadis","year":"2017","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107580_bb0120","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","journal-title":"The American Journal of Psychiatry"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107580_bb0125","doi-asserted-by":"crossref","first-page":"15850","DOI":"10.1074\/jbc.M212816200","article-title":"The vesicular monoamine content regulates VMAT2 activity through Galphaq in mouse platelets. Evidence for autoregulation of vesicular transmitter uptake","volume":"278","author":"Holtje","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2020.107580_bb0130","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1007\/s00415-010-5741-y","article-title":"A brief history of levodopa","volume":"257","author":"Hornykiewicz","year":"2010","journal-title":"Journal of Neurology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107580_bb0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3928\/02793695-20150821-55","article-title":"Deuterated drugs","volume":"53","author":"Howland","year":"2015","journal-title":"Journal of Psychosocial Nursing and Mental Health Services"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107580_bb0140","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial","volume":"66","author":"Huntington Study, G","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107580_bb0145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with Huntington disease: A randomized clinical trial","volume":"316","author":"Huntington Study, G","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2020.107580_bb0150","series-title":"Package insert","author":"Ingrezza","year":"2019"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107580_bb0155","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.410110108","article-title":"Treatment of hyperkinetic movement disorders with tetrabenazine: A double-blind crossover study","volume":"11","author":"Jankovic","year":"1982","journal-title":"Annals of Neurology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107580_bb0160","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S1474-4422(09)70183-8","article-title":"Treatment of hyperkinetic movement disorders","volume":"8","author":"Jankovic","year":"2009","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107580_bb0165","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","article-title":"Long-term effects of tetrabenazine in hyperkinetic movement disorders","volume":"48","author":"Jankovic","year":"1997","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107580_bb0170","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1212\/WNL.38.3.391","article-title":"Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias","volume":"38","author":"Jankovic","year":"1988","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107580_bb0175","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/mds.25996","article-title":"Chorea associated with Huntington\u2019s disease: To treat or not to treat?","volume":"29","author":"Jankovic","year":"2014","journal-title":"Movement Disorders"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107580_bb0180","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000449184","article-title":"Tetrabenazine: Spotlight on drug review","volume":"23","author":"Kaur","year":"2016","journal-title":"Annals of Neurosciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107580_bb0185","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/archneur.58.2.273","article-title":"Progression of symptoms in the early and middle stages of Huntington disease","volume":"58","author":"Kirkwood","year":"2001","journal-title":"Archives of Neurology"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107580_bb0190","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1097\/00004647-199912000-00011","article-title":"Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine","volume":"19","author":"Koeppe","year":"1999","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107580_bb0195","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/00004647-199709000-00001","article-title":"Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography","volume":"17","author":"Koeppe","year":"1997","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107580_bb0200","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.410120308","article-title":"Tetrabenazine has properties of a dopamine receptor antagonist","volume":"12","author":"Login","year":"1982","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107580_bb0205","first-page":"44","article-title":"Single dose and repeat once-daily dose safety, tolerability and pharmacokinetics of valbenazine in healthy male subjects","volume":"47","author":"Luo","year":"2017","journal-title":"Psychopharmacology Bulletin"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107580_bb0210","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/JCP.0000000000001111","article-title":"A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia","volume":"39","author":"Marder","year":"2019","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107580_bb0215","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/jnnp.47.11.1166","article-title":"The treatment of severe dystonia in children and adults","volume":"47","author":"Marsden","year":"1984","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107580_bb0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41398-019-0387-8","article-title":"G protein betagamma subunits play a critical role in the actions of amphetamine","volume":"9","author":"Mauna","year":"2019","journal-title":"Translational Psychiatry"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107580_bb0225","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1007\/s11136-019-02269-8","article-title":"Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia","volume":"28","author":"McEvoy","year":"2019","journal-title":"Quality of Life Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107580_bb0230","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1460-9568.1996.tb01271.x","article-title":"Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrotetrabenazine binding sites","volume":"8","author":"Naudon","year":"1996","journal-title":"The European Journal of Neuroscience"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107580_bb0235","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/mds.26330","article-title":"NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study","volume":"30","author":"O\u2019Brien","year":"2015","journal-title":"Movement Disorders"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107580_bb0240","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1471-4159.2012.07677.x","article-title":"Sources contributing to the average extracellular concentration of dopamine in the nucleus accumbens","volume":"121","author":"Owesson-White","year":"2012","journal-title":"Journal of Neurochemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107580_bb0245","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.wnf.0000136892.24629.96","article-title":"Tetrabenazine treatment in movement disorders","volume":"27","author":"Paleacu","year":"2004","journal-title":"Clinical Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2020.107580_bb0250","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.119.256560","article-title":"Tetrabenazine facilitates exocytosis by enhancing calcium-induced calcium release through ryanodine receptors","volume":"371","author":"de Pascual","year":"2019","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2020.107580_bb0255","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.mam.2012.07.002","article-title":"SLC6 transporters: Structure, function, regulation, disease association and therapeutics","volume":"34","author":"Pramod","year":"2013","journal-title":"Molecular Aspects of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107580_bb0260","first-page":"593","article-title":"Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease","volume":"57","author":"Ranen","year":"1995","journal-title":"American Journal of Human Genetics"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107580_bb0265","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0022-3565(25)33621-9","article-title":"Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain","volume":"225","author":"Reches","year":"1983","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107580_bb0270","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/BF00615962","article-title":"The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders","volume":"29","author":"Roberts","year":"1986","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107580_bb0275","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12035-009-8053-4","article-title":"A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters","volume":"39","author":"Robertson","year":"2009","journal-title":"Molecular Neurobiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107580_bb0280","first-page":"16","article-title":"Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats","volume":"59","author":"Rubinsztein","year":"1996","journal-title":"American Journal of Human Genetics"},{"key":"10.1016\/j.pharmthera.2020.107580_bb0285","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3389\/fphar.2017.00987","article-title":"The case for TAAR1 as a modulator of central nervous system function","volume":"8","author":"Rutigliano","year":"2017","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107580_bb0290","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0021-9258(18)54110-7","article-title":"Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts","volume":"268","author":"Schuldiner","year":"1993","journal-title":"Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107580_bb0295","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1212\/WNL.0000000000005817","article-title":"Evaluating depression and suicidality in tetrabenazine users with Huntington disease","volume":"91","author":"Schultz","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2020.107580_bb0300","first-page":"103","article-title":"Electrophysiological characteristics of dopamine neurons: A 35-year update","author":"Shi","year":"2009","journal-title":"Journal of Neural Transmission. Supplementum"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107580_bb0305","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1523\/JNEUROSCI.5562-08.2009","article-title":"Synaptic overflow of dopamine in the nucleus accumbens arises from neuronal activity in the ventral tegmental area","volume":"29","author":"Sombers","year":"2009","journal-title":"The Journal of Neuroscience"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107580_bb0310","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1017\/S109285291700061X","article-title":"Neuronal traffic signals in tardive dyskinesia: Not enough \u201cstop\u201d in the motor striatum","volume":"22","author":"Stahl","year":"2017","journal-title":"CNS Spectrums"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107580_bb0315","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1017\/S1092852918001219","article-title":"Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: Does one have advantages over the other?","volume":"23","author":"Stahl","year":"2018","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.pharmthera.2020.107580_bb0320","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev.neuro.26.041002.131412","article-title":"The synaptic vesicle cycle","volume":"27","author":"Sudhof","year":"2004","journal-title":"Annual Review of Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107580_bb0325","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/jnnp.35.2.186","article-title":"Treatment of involuntary movement disorders with tetrabenazine","volume":"35","author":"Swash","year":"1972","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107580_bb0330","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/mds.20823","article-title":"Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?","volume":"21","author":"Tarsy","year":"2006","journal-title":"Movement Disorders"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107580_bb0335","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2020.107580_bb0340","article-title":"Amphetamines signal through intracellular TAAR1 receptors coupled to Galpha13 and GalphaS in discrete subcellular domains","author":"Underhill","year":"2019","journal-title":"Molecular Psychiatry"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107580_bb0345","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/med.20187","article-title":"Vesicular monoamine transporters: Structure-function, pharmacology, and medicinal chemistry","volume":"31","author":"Wimalasena","year":"2011","journal-title":"Medicinal Research Reviews"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107580_bb0350","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: A prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2020.107580_bb0355","series-title":"Package insert","author":"Xenazine","year":"2019"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107580_bb0360","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1085\/jgp.201711980","article-title":"The ins and outs of vesicular monoamine transporters","volume":"150","author":"Yaffe","year":"2018","journal-title":"The Journal of General Physiology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107580_bb0365","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.ejmech.2011.02.046","article-title":"Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors","volume":"46","author":"Yao","year":"2011","journal-title":"European Journal of Medicinal Chemistry"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582030108X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582030108X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:07:20Z","timestamp":1759010840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372582030108X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":73,"alternative-id":["S016372582030108X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107580","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VMAT2 inhibitors for the treatment of hyperkinetic movement disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107580"}}